Rigel Pharmaceuticals
RIGL
110 hedge funds and large institutions have $299M invested in Rigel Pharmaceuticals in 2017 Q2 according to their latest regulatory filings, with 16 funds opening new positions, 43 increasing their positions, 31 reducing their positions, and 5 closing their positions.
220% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 5
188% more call options, than puts
Call options by funds: $308K | Put options by funds: $107K
39% more repeat investments, than reductions
Existing positions increased: 43 | Existing positions reduced: 31
11% more funds holding
Funds holding: 99 → 110 (+11)
0.11% more ownership
Funds ownership: 8.83% → 8.94% (+0.11%)
16% less capital invested
Capital invested by funds: $357M → $299M (-$57.1M)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| 1 |
Millennium Management
New York
|
+$5.15M |
| 2 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
+$2.33M |
| 3 |
CM
Crestline Management
Fort Worth,
Texas
|
+$1.29M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$955K |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
+$844K |
Top Sellers
| 1 |
Dimensional Fund Advisors
Austin,
Texas
|
-$1.98M |
| 2 |
SCM
Sio Capital Management
New York
|
-$1.48M |
| 3 |
BlackRock
New York
|
-$1.34M |
| 4 |
Alyeska Investment Group
Chicago,
Illinois
|
-$1.32M |
| 5 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$1.26M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AIM
101
Acrospire Investment Management
Chicago,
Illinois
| $4K | -$7.66K | -280 | -64% |
|
102
Federated Hermes
Pittsburgh,
Pennsylvania
| $4K | -$931 | -34 | -19% |
|
|
MAM
103
Meeder Asset Management
Dublin,
Ohio
| $4K | – | – | – |
|
|
MA
104
MUFG Americas
New York
| $2K | – | – | – |
|
105
Royal Bank of Canada
Toronto,
Ontario, Canada
| $1K | -$12.3K | -451 | -93% |
|
|
PFGIA
106
Patriot Financial Group Insurance Agency
Westborough,
Massachusetts
| $1K | – | – | – |
|
|
SFSIG
107
San Francisco Sentry Investment Group
San Francisco,
California
| $1K | +$821 | +30 | New |
|
|
108
Alyeska Investment Group
Chicago,
Illinois
| – | -$1.32M | -40,028 | Closed |
|
109
Squarepoint
New York
| – | -$97K | -2,939 | Closed |
|
|
SC
110
Savant Capital
Rockford,
Illinois
| – | -$33K | -1,000 | Closed |
|
111
Walleye Trading
New York
| – | -$20 | -600 | Closed |
|
112
Bank of Montreal
Toronto,
Ontario, Canada
| – | +$55 | +2 | New |
|
|
CBT
113
Capital Bank & Trust
Irvine,
California
| – | +$137 | +5 | New |
|
RIGL Hedge Fund Activity: Q2 2017 in Review
110 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Rigel Pharmaceuticals (RIGL) for Q2 2017, worth a combined $299M — down 16% from $357M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new RIGL positions and 5 closed out — a net gain of 11 holders — while 43 added to existing stakes and 31 trimmed.
The largest buyer was Millennium Management, adding an estimated $5.15M. The largest seller was Dimensional Fund Advisors, cutting an estimated $1.98M.
- 110 institutional investors held Rigel Pharmaceuticals (RIGL) as of Q2 2017, up from 99 in Q1 2017.
- Funds reported $299M of Rigel Pharmaceuticals stock for Q2 2017, down 16% quarter-over-quarter.
- 16 funds opened new Rigel Pharmaceuticals positions in Q2 2017 and 5 closed out, a net change of +11 holders.
- The largest Rigel Pharmaceuticals buyer in Q2 2017 was Millennium Management, an estimated $5.15M added.
- The largest Rigel Pharmaceuticals seller in Q2 2017 was Dimensional Fund Advisors, an estimated $1.98M sold.
Based on aggregated 13F filings for Q2 2017.